nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA6—saliva—attention deficit hyperactivity disorder	0.0267	0.0437	CbGeAlD
Nilotinib—EPHB2—forebrain—attention deficit hyperactivity disorder	0.0111	0.0181	CbGeAlD
Nilotinib—CDC42BPB—forebrain—attention deficit hyperactivity disorder	0.0098	0.016	CbGeAlD
Nilotinib—MAPK8—forebrain—attention deficit hyperactivity disorder	0.00887	0.0145	CbGeAlD
Nilotinib—CDC42BPB—cardiovascular system—attention deficit hyperactivity disorder	0.00829	0.0136	CbGeAlD
Nilotinib—MAPK8—cardiovascular system—attention deficit hyperactivity disorder	0.0075	0.0123	CbGeAlD
Nilotinib—EPHB3—forebrain—attention deficit hyperactivity disorder	0.00731	0.012	CbGeAlD
Nilotinib—HCK—forebrain—attention deficit hyperactivity disorder	0.00672	0.011	CbGeAlD
Nilotinib—TIE1—cardiovascular system—attention deficit hyperactivity disorder	0.0065	0.0106	CbGeAlD
Nilotinib—CDC42BPB—midbrain—attention deficit hyperactivity disorder	0.00647	0.0106	CbGeAlD
Nilotinib—EPHA4—forebrain—attention deficit hyperactivity disorder	0.00611	0.00999	CbGeAlD
Nilotinib—CA3—forebrain—attention deficit hyperactivity disorder	0.00603	0.00987	CbGeAlD
Nilotinib—EPHB2—nervous system—attention deficit hyperactivity disorder	0.00602	0.00985	CbGeAlD
Nilotinib—MAPK8—midbrain—attention deficit hyperactivity disorder	0.00586	0.00958	CbGeAlD
Nilotinib—EPHB2—central nervous system—attention deficit hyperactivity disorder	0.0058	0.00948	CbGeAlD
Nilotinib—EPHA8—nervous system—attention deficit hyperactivity disorder	0.00577	0.00944	CbGeAlD
Nilotinib—MAPK14—forebrain—attention deficit hyperactivity disorder	0.00563	0.00921	CbGeAlD
Nilotinib—EPHA8—central nervous system—attention deficit hyperactivity disorder	0.00556	0.00909	CbGeAlD
Nilotinib—EPHA8—cerebellum—attention deficit hyperactivity disorder	0.00543	0.00889	CbGeAlD
Nilotinib—MAPK11—nervous system—attention deficit hyperactivity disorder	0.00537	0.00878	CbGeAlD
Nilotinib—CDC42BPB—nervous system—attention deficit hyperactivity disorder	0.00532	0.00871	CbGeAlD
Nilotinib—MAPK11—central nervous system—attention deficit hyperactivity disorder	0.00517	0.00845	CbGeAlD
Nilotinib—CDC42BPB—central nervous system—attention deficit hyperactivity disorder	0.00512	0.00838	CbGeAlD
Nilotinib—CA3—cardiovascular system—attention deficit hyperactivity disorder	0.0051	0.00834	CbGeAlD
Nilotinib—MAPK11—cerebellum—attention deficit hyperactivity disorder	0.00505	0.00826	CbGeAlD
Nilotinib—EPHA3—nervous system—attention deficit hyperactivity disorder	0.00505	0.00825	CbGeAlD
Nilotinib—CDC42BPB—cerebellum—attention deficit hyperactivity disorder	0.00501	0.00819	CbGeAlD
Nilotinib—EPHB6—forebrain—attention deficit hyperactivity disorder	0.00488	0.00799	CbGeAlD
Nilotinib—BRAF—midbrain—attention deficit hyperactivity disorder	0.00487	0.00796	CbGeAlD
Nilotinib—EPHA3—central nervous system—attention deficit hyperactivity disorder	0.00486	0.00795	CbGeAlD
Nilotinib—MAPK8—nervous system—attention deficit hyperactivity disorder	0.00481	0.00787	CbGeAlD
Nilotinib—EPHA6—nervous system—attention deficit hyperactivity disorder	0.00481	0.00787	CbGeAlD
Nilotinib—MAPK14—cardiovascular system—attention deficit hyperactivity disorder	0.00476	0.00779	CbGeAlD
Nilotinib—FGR—cardiovascular system—attention deficit hyperactivity disorder	0.00474	0.00776	CbGeAlD
Nilotinib—MAPK8—central nervous system—attention deficit hyperactivity disorder	0.00463	0.00758	CbGeAlD
Nilotinib—EPHA6—central nervous system—attention deficit hyperactivity disorder	0.00463	0.00758	CbGeAlD
Nilotinib—PDGFRA—forebrain—attention deficit hyperactivity disorder	0.00463	0.00757	CbGeAlD
Nilotinib—EPHB2—brain—attention deficit hyperactivity disorder	0.0046	0.00753	CbGeAlD
Nilotinib—MAPK8—cerebellum—attention deficit hyperactivity disorder	0.00453	0.00741	CbGeAlD
Nilotinib—EPHB4—cardiovascular system—attention deficit hyperactivity disorder	0.00451	0.00738	CbGeAlD
Nilotinib—LYN—nervous system—attention deficit hyperactivity disorder	0.00444	0.00727	CbGeAlD
Nilotinib—HCK—midbrain—attention deficit hyperactivity disorder	0.00444	0.00726	CbGeAlD
Nilotinib—EPHA2—cardiovascular system—attention deficit hyperactivity disorder	0.00443	0.00724	CbGeAlD
Nilotinib—EPHA8—brain—attention deficit hyperactivity disorder	0.00441	0.00722	CbGeAlD
Nilotinib—CA7—midbrain—attention deficit hyperactivity disorder	0.00434	0.0071	CbGeAlD
Nilotinib—TEK—cardiovascular system—attention deficit hyperactivity disorder	0.00432	0.00707	CbGeAlD
Nilotinib—LYN—central nervous system—attention deficit hyperactivity disorder	0.00428	0.007	CbGeAlD
Nilotinib—CA12—forebrain—attention deficit hyperactivity disorder	0.00427	0.00699	CbGeAlD
Nilotinib—TIE1—nervous system—attention deficit hyperactivity disorder	0.00417	0.00683	CbGeAlD
Nilotinib—MAPK11—brain—attention deficit hyperactivity disorder	0.0041	0.00671	CbGeAlD
Nilotinib—CSF1R—forebrain—attention deficit hyperactivity disorder	0.00407	0.00667	CbGeAlD
Nilotinib—CDC42BPB—brain—attention deficit hyperactivity disorder	0.00407	0.00665	CbGeAlD
Nilotinib—TIE1—central nervous system—attention deficit hyperactivity disorder	0.00402	0.00657	CbGeAlD
Nilotinib—EPHB3—nervous system—attention deficit hyperactivity disorder	0.00397	0.00649	CbGeAlD
Nilotinib—TIE1—cerebellum—attention deficit hyperactivity disorder	0.00393	0.00642	CbGeAlD
Nilotinib—PDGFRA—cardiovascular system—attention deficit hyperactivity disorder	0.00391	0.0064	CbGeAlD
Nilotinib—EPHA3—brain—attention deficit hyperactivity disorder	0.00386	0.00631	CbGeAlD
Nilotinib—EPHB3—central nervous system—attention deficit hyperactivity disorder	0.00382	0.00625	CbGeAlD
Nilotinib—BRAF—cerebellum—attention deficit hyperactivity disorder	0.00377	0.00616	CbGeAlD
Nilotinib—EPHB3—cerebellum—attention deficit hyperactivity disorder	0.00374	0.00611	CbGeAlD
Nilotinib—MAPK8—brain—attention deficit hyperactivity disorder	0.00368	0.00602	CbGeAlD
Nilotinib—EPHA6—brain—attention deficit hyperactivity disorder	0.00368	0.00602	CbGeAlD
Nilotinib—HCK—nervous system—attention deficit hyperactivity disorder	0.00365	0.00597	CbGeAlD
Nilotinib—CA14—midbrain—attention deficit hyperactivity disorder	0.00362	0.00592	CbGeAlD
Nilotinib—MAP2K5—cardiovascular system—attention deficit hyperactivity disorder	0.00353	0.00577	CbGeAlD
Nilotinib—EPHB4—midbrain—attention deficit hyperactivity disorder	0.00353	0.00577	CbGeAlD
Nilotinib—HCK—central nervous system—attention deficit hyperactivity disorder	0.00351	0.00574	CbGeAlD
Nilotinib—CSF1R—cardiovascular system—attention deficit hyperactivity disorder	0.00345	0.00564	CbGeAlD
Nilotinib—ABL2—cerebellum—attention deficit hyperactivity disorder	0.00341	0.00558	CbGeAlD
Nilotinib—LYN—brain—attention deficit hyperactivity disorder	0.0034	0.00555	CbGeAlD
Nilotinib—CA1—forebrain—attention deficit hyperactivity disorder	0.00338	0.00554	CbGeAlD
Nilotinib—TEK—midbrain—attention deficit hyperactivity disorder	0.00337	0.00552	CbGeAlD
Nilotinib—CA7—cerebellum—attention deficit hyperactivity disorder	0.00336	0.00549	CbGeAlD
Nilotinib—MAP4K1—brain—attention deficit hyperactivity disorder	0.00334	0.00547	CbGeAlD
Nilotinib—EPHA4—nervous system—attention deficit hyperactivity disorder	0.00332	0.00542	CbGeAlD
Nilotinib—CA3—nervous system—attention deficit hyperactivity disorder	0.00327	0.00536	CbGeAlD
Nilotinib—EPHB6—midbrain—attention deficit hyperactivity disorder	0.00322	0.00527	CbGeAlD
Nilotinib—EPHA4—central nervous system—attention deficit hyperactivity disorder	0.00319	0.00522	CbGeAlD
Nilotinib—TIE1—brain—attention deficit hyperactivity disorder	0.00319	0.00522	CbGeAlD
Nilotinib—CA3—central nervous system—attention deficit hyperactivity disorder	0.00315	0.00516	CbGeAlD
Nilotinib—KIT—cardiovascular system—attention deficit hyperactivity disorder	0.00313	0.00512	CbGeAlD
Nilotinib—EPHA4—cerebellum—attention deficit hyperactivity disorder	0.00312	0.0051	CbGeAlD
Nilotinib—BRAF—brain—attention deficit hyperactivity disorder	0.00306	0.005	CbGeAlD
Nilotinib—MAPK14—nervous system—attention deficit hyperactivity disorder	0.00306	0.005	CbGeAlD
Nilotinib—PDGFRB—cardiovascular system—attention deficit hyperactivity disorder	0.00306	0.005	CbGeAlD
Nilotinib—FGR—nervous system—attention deficit hyperactivity disorder	0.00304	0.00498	CbGeAlD
Nilotinib—EPHB3—brain—attention deficit hyperactivity disorder	0.00303	0.00496	CbGeAlD
Nilotinib—CA9—cerebellum—attention deficit hyperactivity disorder	0.00295	0.00483	CbGeAlD
Nilotinib—MAPK14—central nervous system—attention deficit hyperactivity disorder	0.00294	0.00481	CbGeAlD
Nilotinib—FGR—central nervous system—attention deficit hyperactivity disorder	0.00293	0.00479	CbGeAlD
Nilotinib—MAPK14—cerebellum—attention deficit hyperactivity disorder	0.00288	0.00471	CbGeAlD
Nilotinib—CA1—cardiovascular system—attention deficit hyperactivity disorder	0.00286	0.00468	CbGeAlD
Nilotinib—EPHA2—nervous system—attention deficit hyperactivity disorder	0.00284	0.00465	CbGeAlD
Nilotinib—CA14—cerebellum—attention deficit hyperactivity disorder	0.0028	0.00458	CbGeAlD
Nilotinib—HCK—brain—attention deficit hyperactivity disorder	0.00279	0.00456	CbGeAlD
Nilotinib—TEK—nervous system—attention deficit hyperactivity disorder	0.00277	0.00454	CbGeAlD
Nilotinib—ABL2—brain—attention deficit hyperactivity disorder	0.00277	0.00453	CbGeAlD
Nilotinib—MAP2K5—midbrain—attention deficit hyperactivity disorder	0.00276	0.00451	CbGeAlD
Nilotinib—EPHA2—central nervous system—attention deficit hyperactivity disorder	0.00274	0.00448	CbGeAlD
Nilotinib—CA7—brain—attention deficit hyperactivity disorder	0.00273	0.00446	CbGeAlD
Nilotinib—EPHB4—cerebellum—attention deficit hyperactivity disorder	0.00273	0.00446	CbGeAlD
Nilotinib—ABL1—cardiovascular system—attention deficit hyperactivity disorder	0.00272	0.00446	CbGeAlD
Nilotinib—CSF1R—midbrain—attention deficit hyperactivity disorder	0.00269	0.0044	CbGeAlD
Nilotinib—TEK—central nervous system—attention deficit hyperactivity disorder	0.00267	0.00437	CbGeAlD
Nilotinib—EPHB6—nervous system—attention deficit hyperactivity disorder	0.00265	0.00434	CbGeAlD
Nilotinib—CA4—forebrain—attention deficit hyperactivity disorder	0.00265	0.00433	CbGeAlD
Nilotinib—TEK—cerebellum—attention deficit hyperactivity disorder	0.00261	0.00427	CbGeAlD
Nilotinib—EPHB6—central nervous system—attention deficit hyperactivity disorder	0.00255	0.00417	CbGeAlD
Nilotinib—EPHA4—brain—attention deficit hyperactivity disorder	0.00253	0.00415	CbGeAlD
Nilotinib—PDGFRA—nervous system—attention deficit hyperactivity disorder	0.00251	0.00411	CbGeAlD
Nilotinib—CA3—brain—attention deficit hyperactivity disorder	0.0025	0.00409	CbGeAlD
Nilotinib—EPHB6—cerebellum—attention deficit hyperactivity disorder	0.00249	0.00408	CbGeAlD
Nilotinib—KIT—midbrain—attention deficit hyperactivity disorder	0.00244	0.004	CbGeAlD
Nilotinib—PDGFRA—central nervous system—attention deficit hyperactivity disorder	0.00242	0.00396	CbGeAlD
Nilotinib—PDGFRB—midbrain—attention deficit hyperactivity disorder	0.00239	0.0039	CbGeAlD
Nilotinib—PDGFRA—cerebellum—attention deficit hyperactivity disorder	0.00236	0.00387	CbGeAlD
Nilotinib—MAPK14—brain—attention deficit hyperactivity disorder	0.00234	0.00382	CbGeAlD
Nilotinib—FGR—brain—attention deficit hyperactivity disorder	0.00233	0.00381	CbGeAlD
Nilotinib—CA12—nervous system—attention deficit hyperactivity disorder	0.00232	0.00379	CbGeAlD
Nilotinib—CA14—brain—attention deficit hyperactivity disorder	0.00227	0.00372	CbGeAlD
Nilotinib—MAP2K5—nervous system—attention deficit hyperactivity disorder	0.00227	0.00371	CbGeAlD
Nilotinib—CA4—cardiovascular system—attention deficit hyperactivity disorder	0.00224	0.00366	CbGeAlD
Nilotinib—CA12—central nervous system—attention deficit hyperactivity disorder	0.00223	0.00365	CbGeAlD
Nilotinib—EPHB4—brain—attention deficit hyperactivity disorder	0.00222	0.00362	CbGeAlD
Nilotinib—CSF1R—nervous system—attention deficit hyperactivity disorder	0.00221	0.00362	CbGeAlD
Nilotinib—CA2—forebrain—attention deficit hyperactivity disorder	0.00219	0.00359	CbGeAlD
Nilotinib—MAP2K5—central nervous system—attention deficit hyperactivity disorder	0.00218	0.00357	CbGeAlD
Nilotinib—EPHA2—brain—attention deficit hyperactivity disorder	0.00217	0.00355	CbGeAlD
Nilotinib—MAP2K5—cerebellum—attention deficit hyperactivity disorder	0.00213	0.00349	CbGeAlD
Nilotinib—CSF1R—central nervous system—attention deficit hyperactivity disorder	0.00213	0.00348	CbGeAlD
Nilotinib—ABL1—midbrain—attention deficit hyperactivity disorder	0.00213	0.00348	CbGeAlD
Nilotinib—TEK—brain—attention deficit hyperactivity disorder	0.00212	0.00347	CbGeAlD
Nilotinib—CSF1R—cerebellum—attention deficit hyperactivity disorder	0.00208	0.0034	CbGeAlD
Nilotinib—EPHB6—brain—attention deficit hyperactivity disorder	0.00203	0.00331	CbGeAlD
Nilotinib—KIT—nervous system—attention deficit hyperactivity disorder	0.00201	0.00329	CbGeAlD
Nilotinib—PDGFRB—nervous system—attention deficit hyperactivity disorder	0.00196	0.00321	CbGeAlD
Nilotinib—KIT—central nervous system—attention deficit hyperactivity disorder	0.00193	0.00316	CbGeAlD
Nilotinib—PDGFRA—brain—attention deficit hyperactivity disorder	0.00192	0.00314	CbGeAlD
Nilotinib—KIT—cerebellum—attention deficit hyperactivity disorder	0.00189	0.00309	CbGeAlD
Nilotinib—PDGFRB—central nervous system—attention deficit hyperactivity disorder	0.00189	0.00309	CbGeAlD
Nilotinib—CA2—cardiovascular system—attention deficit hyperactivity disorder	0.00185	0.00303	CbGeAlD
Nilotinib—PDGFRB—cerebellum—attention deficit hyperactivity disorder	0.00185	0.00302	CbGeAlD
Nilotinib—CA1—nervous system—attention deficit hyperactivity disorder	0.00184	0.00301	CbGeAlD
Nilotinib—CA12—brain—attention deficit hyperactivity disorder	0.00177	0.0029	CbGeAlD
Nilotinib—CA1—central nervous system—attention deficit hyperactivity disorder	0.00177	0.00289	CbGeAlD
Nilotinib—ABL1—nervous system—attention deficit hyperactivity disorder	0.00175	0.00286	CbGeAlD
Nilotinib—CA4—midbrain—attention deficit hyperactivity disorder	0.00175	0.00286	CbGeAlD
Nilotinib—MAP2K5—brain—attention deficit hyperactivity disorder	0.00173	0.00283	CbGeAlD
Nilotinib—CSF1R—brain—attention deficit hyperactivity disorder	0.00169	0.00277	CbGeAlD
Nilotinib—ABL1—central nervous system—attention deficit hyperactivity disorder	0.00168	0.00275	CbGeAlD
Nilotinib—ABL1—cerebellum—attention deficit hyperactivity disorder	0.00165	0.00269	CbGeAlD
Nilotinib—CYP2B6—cardiovascular system—attention deficit hyperactivity disorder	0.00158	0.00259	CbGeAlD
Nilotinib—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.00157	0.00257	CbGeAlD
Nilotinib—KIT—brain—attention deficit hyperactivity disorder	0.00154	0.00251	CbGeAlD
Nilotinib—PDGFRB—brain—attention deficit hyperactivity disorder	0.0015	0.00245	CbGeAlD
Nilotinib—CA2—midbrain—attention deficit hyperactivity disorder	0.00145	0.00237	CbGeAlD
Nilotinib—CA4—nervous system—attention deficit hyperactivity disorder	0.00144	0.00235	CbGeAlD
Nilotinib—CA1—brain—attention deficit hyperactivity disorder	0.0014	0.0023	CbGeAlD
Nilotinib—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.00139	0.00228	CbGeAlD
Nilotinib—CA4—central nervous system—attention deficit hyperactivity disorder	0.00138	0.00226	CbGeAlD
Nilotinib—CA4—cerebellum—attention deficit hyperactivity disorder	0.00135	0.00221	CbGeAlD
Nilotinib—ABCG2—midbrain—attention deficit hyperactivity disorder	0.00134	0.00219	CbGeAlD
Nilotinib—ABL1—brain—attention deficit hyperactivity disorder	0.00134	0.00219	CbGeAlD
Nilotinib—CA2—nervous system—attention deficit hyperactivity disorder	0.00119	0.00195	CbGeAlD
Nilotinib—CA2—central nervous system—attention deficit hyperactivity disorder	0.00115	0.00188	CbGeAlD
Nilotinib—CA2—cerebellum—attention deficit hyperactivity disorder	0.00112	0.00183	CbGeAlD
Nilotinib—CA4—brain—attention deficit hyperactivity disorder	0.0011	0.0018	CbGeAlD
Nilotinib—ABCG2—cerebellum—attention deficit hyperactivity disorder	0.00104	0.0017	CbGeAlD
Nilotinib—CYP2B6—nervous system—attention deficit hyperactivity disorder	0.00102	0.00166	CbGeAlD
Nilotinib—ABCB1—forebrain—attention deficit hyperactivity disorder	0.001	0.00164	CbGeAlD
Nilotinib—CYP2B6—central nervous system—attention deficit hyperactivity disorder	0.000979	0.0016	CbGeAlD
Nilotinib—CA2—brain—attention deficit hyperactivity disorder	0.00091	0.00149	CbGeAlD
Nilotinib—CYP2C8—brain—attention deficit hyperactivity disorder	0.000867	0.00142	CbGeAlD
Nilotinib—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000847	0.00139	CbGeAlD
Nilotinib—ABCG2—brain—attention deficit hyperactivity disorder	0.000843	0.00138	CbGeAlD
Nilotinib—CYP2B6—brain—attention deficit hyperactivity disorder	0.000778	0.00127	CbGeAlD
Nilotinib—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000768	0.00126	CbGeAlD
Nilotinib—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000756	0.00124	CbGeAlD
Nilotinib—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00074	0.00121	CbGeAlD
Nilotinib—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000728	0.00119	CbGeAlD
Nilotinib—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000711	0.00116	CbGeAlD
Nilotinib—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000661	0.00108	CbGeAlD
Nilotinib—CYP2D6—brain—attention deficit hyperactivity disorder	0.000578	0.000945	CbGeAlD
Nilotinib—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000544	0.000889	CbGeAlD
Nilotinib—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000524	0.000856	CbGeAlD
Nilotinib—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000512	0.000837	CbGeAlD
Nilotinib—ABCB1—brain—attention deficit hyperactivity disorder	0.000416	0.00068	CbGeAlD
Nilotinib—CA9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000168	0.000431	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000165	0.000425	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000162	0.000416	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000162	0.000416	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000161	0.000415	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00016	0.000412	CbGpPWpGaD
Nilotinib—CA9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00016	0.000411	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000159	0.000408	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000158	0.000408	CbGpPWpGaD
Nilotinib—CA4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000157	0.000405	CbGpPWpGaD
Nilotinib—CA4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000156	0.000402	CbGpPWpGaD
Nilotinib—CA3—Metabolism—EP300—attention deficit hyperactivity disorder	0.000156	0.000401	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000155	0.0004	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000154	0.000397	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000154	0.000395	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000153	0.000394	CbGpPWpGaD
Nilotinib—KIT—Disease—SNAP25—attention deficit hyperactivity disorder	0.000153	0.000393	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000152	0.000391	CbGpPWpGaD
Nilotinib—CA2—Metabolism—COMT—attention deficit hyperactivity disorder	0.000151	0.000388	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00015	0.000386	CbGpPWpGaD
Nilotinib—CA2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00015	0.000385	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000149	0.000383	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000147	0.000379	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000146	0.000375	CbGpPWpGaD
Nilotinib—CA1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000145	0.000372	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000144	0.000372	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—SNAP25—attention deficit hyperactivity disorder	0.000144	0.000372	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000144	0.000371	CbGpPWpGaD
Nilotinib—CA1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000143	0.000369	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000142	0.000366	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000142	0.000365	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000142	0.000364	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000141	0.000364	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00014	0.00036	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000137	0.000352	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.000136	0.000351	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000135	0.000346	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000133	0.000342	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000133	0.000341	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000131	0.000338	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00013	0.000335	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—SNAP25—attention deficit hyperactivity disorder	0.00013	0.000335	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00013	0.000334	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000128	0.00033	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000128	0.000329	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000127	0.000328	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000127	0.000328	CbGpPWpGaD
Nilotinib—CA9—Metabolism—COMT—attention deficit hyperactivity disorder	0.000127	0.000327	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000126	0.000325	CbGpPWpGaD
Nilotinib—CA9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000126	0.000325	CbGpPWpGaD
Nilotinib—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000125	0.000322	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000125	0.000321	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000125	0.000321	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000124	0.00032	CbGpPWpGaD
Nilotinib—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000124	0.00032	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000124	0.000319	CbGpPWpGaD
Nilotinib—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000123	0.000317	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000123	0.000316	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000118	0.000305	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000117	0.000302	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000116	0.000298	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000115	0.000296	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000115	0.000295	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000114	0.000294	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000114	0.000293	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000113	0.00029	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000113	0.00029	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000112	0.000289	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000112	0.000288	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000111	0.000287	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00011	0.000284	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00011	0.000283	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000109	0.00028	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000107	0.000275	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000106	0.000273	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000106	0.000273	CbGpPWpGaD
Nilotinib—LCK—Disease—SNAP25—attention deficit hyperactivity disorder	0.000104	0.000269	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000104	0.000268	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000104	0.000268	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000104	0.000267	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000103	0.000266	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000103	0.000265	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000102	0.000263	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000102	0.000262	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000101	0.00026	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.0001	0.000259	CbGpPWpGaD
Nilotinib—CA14—Metabolism—EP300—attention deficit hyperactivity disorder	0.0001	0.000258	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.98e-05	0.000257	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.8e-05	0.000252	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.8e-05	0.000252	CbGpPWpGaD
Nilotinib—CA6—Metabolism—EP300—attention deficit hyperactivity disorder	9.78e-05	0.000252	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.69e-05	0.000249	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.63e-05	0.000248	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.6e-05	0.000247	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	9.53e-05	0.000245	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.51e-05	0.000245	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	9.5e-05	0.000245	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9.36e-05	0.000241	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—EP300—attention deficit hyperactivity disorder	9.22e-05	0.000237	CbGpPWpGaD
Nilotinib—CA7—Metabolism—EP300—attention deficit hyperactivity disorder	9.13e-05	0.000235	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.12e-05	0.000235	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.11e-05	0.000234	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.1e-05	0.000234	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	9e-05	0.000232	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.92e-05	0.00023	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.86e-05	0.000228	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.82e-05	0.000227	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—EP300—attention deficit hyperactivity disorder	8.73e-05	0.000225	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—EP300—attention deficit hyperactivity disorder	8.72e-05	0.000224	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	8.72e-05	0.000224	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—EP300—attention deficit hyperactivity disorder	8.68e-05	0.000223	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.67e-05	0.000223	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.67e-05	0.000223	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.64e-05	0.000222	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.57e-05	0.00022	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—EP300—attention deficit hyperactivity disorder	8.55e-05	0.00022	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—EP300—attention deficit hyperactivity disorder	8.51e-05	0.000219	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.49e-05	0.000219	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.47e-05	0.000218	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.46e-05	0.000218	CbGpPWpGaD
Nilotinib—CA12—Metabolism—EP300—attention deficit hyperactivity disorder	8.45e-05	0.000218	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.39e-05	0.000216	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	8.3e-05	0.000214	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—EP300—attention deficit hyperactivity disorder	8.26e-05	0.000213	CbGpPWpGaD
Nilotinib—HCK—Immune System—EP300—attention deficit hyperactivity disorder	8.25e-05	0.000212	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.19e-05	0.000211	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—EP300—attention deficit hyperactivity disorder	8.11e-05	0.000209	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.06e-05	0.000208	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.05e-05	0.000207	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	8e-05	0.000206	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.98e-05	0.000205	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.95e-05	0.000205	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.87e-05	0.000202	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.86e-05	0.000202	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.82e-05	0.000201	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.81e-05	0.000201	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—TPH2—attention deficit hyperactivity disorder	7.77e-05	0.0002	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.77e-05	0.0002	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.75e-05	0.0002	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.7e-05	0.000198	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.66e-05	0.000197	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—DPYD—attention deficit hyperactivity disorder	7.64e-05	0.000197	CbGpPWpGaD
Nilotinib—HCK—Disease—EP300—attention deficit hyperactivity disorder	7.62e-05	0.000196	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—COMT—attention deficit hyperactivity disorder	7.57e-05	0.000195	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	7.51e-05	0.000193	CbGpPWpGaD
Nilotinib—BLK—Immune System—EP300—attention deficit hyperactivity disorder	7.48e-05	0.000192	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—EP300—attention deficit hyperactivity disorder	7.48e-05	0.000192	CbGpPWpGaD
Nilotinib—FGR—Immune System—EP300—attention deficit hyperactivity disorder	7.45e-05	0.000192	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.41e-05	0.000191	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.31e-05	0.000188	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.3e-05	0.000188	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.27e-05	0.000187	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.2e-05	0.000185	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.1e-05	0.000183	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.08e-05	0.000182	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—EP300—attention deficit hyperactivity disorder	7.01e-05	0.00018	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.96e-05	0.000179	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.88e-05	0.000177	CbGpPWpGaD
Nilotinib—CA4—Metabolism—EP300—attention deficit hyperactivity disorder	6.74e-05	0.000173	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	6.58e-05	0.000169	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.58e-05	0.000169	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.55e-05	0.000169	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	6.47e-05	0.000166	CbGpPWpGaD
Nilotinib—CA2—Metabolism—EP300—attention deficit hyperactivity disorder	6.46e-05	0.000166	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—COMT—attention deficit hyperactivity disorder	6.42e-05	0.000165	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.4e-05	0.000165	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—MAOA—attention deficit hyperactivity disorder	6.38e-05	0.000164	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—EP300—attention deficit hyperactivity disorder	6.31e-05	0.000162	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.21e-05	0.00016	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.2e-05	0.00016	CbGpPWpGaD
Nilotinib—CA1—Metabolism—EP300—attention deficit hyperactivity disorder	6.2e-05	0.000159	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.01e-05	0.000155	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EP300—attention deficit hyperactivity disorder	5.96e-05	0.000153	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.91e-05	0.000152	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	5.73e-05	0.000147	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.73e-05	0.000147	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	5.64e-05	0.000145	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.59e-05	0.000144	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.47e-05	0.000141	CbGpPWpGaD
Nilotinib—BRAF—Disease—EP300—attention deficit hyperactivity disorder	5.45e-05	0.00014	CbGpPWpGaD
Nilotinib—CA9—Metabolism—EP300—attention deficit hyperactivity disorder	5.45e-05	0.00014	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	5.4e-05	0.000139	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.4e-05	0.000139	CbGpPWpGaD
Nilotinib—KIT—Immune System—EP300—attention deficit hyperactivity disorder	5.37e-05	0.000138	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	5.35e-05	0.000138	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.35e-05	0.000138	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	5.31e-05	0.000137	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	5.27e-05	0.000135	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.26e-05	0.000135	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.24e-05	0.000135	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.19e-05	0.000133	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	5.11e-05	0.000132	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EP300—attention deficit hyperactivity disorder	5.08e-05	0.000131	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5e-05	0.000129	CbGpPWpGaD
Nilotinib—KIT—Disease—EP300—attention deficit hyperactivity disorder	4.96e-05	0.000128	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.94e-05	0.000127	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.9e-05	0.000126	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.83e-05	0.000124	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—COMT—attention deficit hyperactivity disorder	4.71e-05	0.000121	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EP300—attention deficit hyperactivity disorder	4.69e-05	0.000121	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MAOA—attention deficit hyperactivity disorder	4.67e-05	0.00012	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.6e-05	0.000118	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EP300—attention deficit hyperactivity disorder	4.58e-05	0.000118	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.58e-05	0.000118	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.49e-05	0.000115	CbGpPWpGaD
Nilotinib—LYN—Immune System—EP300—attention deficit hyperactivity disorder	4.48e-05	0.000115	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EP300—attention deficit hyperactivity disorder	4.46e-05	0.000115	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.36e-05	0.000112	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.32e-05	0.000111	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.28e-05	0.00011	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EP300—attention deficit hyperactivity disorder	4.25e-05	0.000109	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EP300—attention deficit hyperactivity disorder	4.23e-05	0.000109	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.11e-05	0.000106	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.07e-05	0.000105	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	3.98e-05	0.000103	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	3.96e-05	0.000102	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.85e-05	9.91e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	3.84e-05	9.87e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.82e-05	9.82e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EP300—attention deficit hyperactivity disorder	3.68e-05	9.46e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	3.53e-05	9.08e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.53e-05	9.08e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	3.47e-05	8.94e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.47e-05	8.94e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	3.47e-05	8.93e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	3.45e-05	8.87e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EP300—attention deficit hyperactivity disorder	3.39e-05	8.73e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.29e-05	8.46e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	3.27e-05	8.42e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	3.25e-05	8.36e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—EP300—attention deficit hyperactivity disorder	3.24e-05	8.35e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	3.24e-05	8.34e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.23e-05	8.31e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	3.22e-05	8.29e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	3.12e-05	8.04e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.96e-05	7.62e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.9e-05	7.46e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.82e-05	7.26e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—EP300—attention deficit hyperactivity disorder	2.75e-05	7.08e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.75e-05	7.07e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.69e-05	6.91e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.38e-05	6.12e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	2.14e-05	5.5e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	2.12e-05	5.46e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—EP300—attention deficit hyperactivity disorder	2.02e-05	5.19e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	1.71e-05	4.4e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	1.49e-05	3.83e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	1.4e-05	3.61e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	1.39e-05	3.58e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	9.17e-06	2.36e-05	CbGpPWpGaD
